Singh, Grisuna
(Department of Anesthesiology and Intensive Care, Nepalgunj Medical College and Teaching Hospital)
,
Song, Sejin
(Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
,
Choi, Eunjoo
(Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
,
Lee, Pyung-Bok
(Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
,
Nahm, Francis Sahngun
(Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®...
Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines and discusses the advantage of RZV over LZV based on the available literature.
Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines and discusses the advantage of RZV over LZV based on the available literature.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
문제 정의
In this paper, we review the market-available vaccines for HZ and PHN prevention and compare the efficacy, safety, and advantages of the RZV and LZV vaccines. This review will help pain management specialists better understand the vaccine against HZ and PHN.
가설 설정
4. Will an additional vaccination with Shingrix® be advisable for patients that previously received the Zostavax® vaccination?
제안 방법
In this paper, we review the market-available vaccines for HZ and PHN prevention and compare the efficacy, safety, and advantages of the RZV and LZV vaccines. This review will help pain management specialists better understand the vaccine against HZ and PHN.
The short-term persistence sub-study (STPS) was conducted approximately 15 months after the SPS, and followed up for 3.3-7.8 years after vaccination. It was conducted at 12 sites with a study population of 14,270, who were also involved in the SPS group.
대상 데이터
The ZOE-70 study was a separate study conducted at the same time in individuals 70 years or older to establish the safety and efficacy of the vaccine in that specific age group (Table 3) [11]. A total of 16,160 adults in 18 countries were involved in the ZOE-50 study. A total of 14,759 adults were given two doses of vaccine or placebo, out of which 216 adults (6 cases in the immunization group and 210 cases in the placebo group) were diagnosed with confirmed cases of HZ.
8 years after vaccination. It was conducted at 12 sites with a study population of 14,270, who were also involved in the SPS group. This study showed that the effect of Zostavax® decreased throughout the 3.
This study enrolled 6,867 vaccinated adults without a placebo group from the SPS study; vaccine efficacy for HZ burden of illness declined and the incidence of HZ and PHN declined from years 7 to 11 after Zostavax® vaccination.
성능/효과
In this study, RZV showed significantly higher efficacy compared to LZV in HZ prevention in adults ≥ 60 years (92% for RZV vs. 51% for LZV).
RZV (Shingrix®), a non-live vaccine containing recombinant glycoprotein E with a new adjuvant (ASO1B), is preferable to LZV and has been increasingly used since its launch in 2017, mainly because of its higher efficacy. The new RZV vaccine showed favorable outcomes in various population subgroups, including different races, adults with a history of HZ, individuals previously vaccinated with Zostavax®, and even immune-compromised individuals and transplant recipients. This new vaccine will protect many people from the risk of HZ and subsequent PHN.
참고문헌 (43)
1 Jeon YH 2015 Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment Korean J Pain 28 177 84 10.3344/kjp.2015.28.3.177 26175877
2 Gilden DH Kleinschmidt-DeMasters BK LaGuardia JJ Mahalingam R Cohrs RJ 2000 Neurologic complications of the reactivation of varicella-zoster virus N Engl J Med 342 635 45 10.1056/NEJM200003023420906 10699164
6 Leung J Harpaz R Molinari NA Jumaan A Zhou F 2011 Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination Clin Infect Dis 52 332 40 10.1093/cid/ciq077 21217180
9 Hong MJ Kim YD Cheong YK Park SJ Choi SW Hong HJ 2016 Epidemiology of postherpetic neuralgia in Korea: an electronic population health insurance system based study Medicine (Baltimore) 95 e3304 10.1097/MD.0000000000003304 27057902
11 Cunningham AL Lal H Kovac M Chlibek R Hwang SJ Diez-Domingo J 2016 Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older N Engl J Med 375 1019 32 10.1056/NEJMoa1603800 27626517
12 Weller TH Witton HM Bell EJ 1958 The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro J Exp Med 108 843 68 10.1084/jem.108.6.843 13598816
13 Takahashi M Otsuka T Okuno Y Asano Y Yazaki T 1974 Live vaccine used to prevent the spread of varicella in children in hospital Lancet 2 1288 90 10.1016/S0140-6736(74)90144-5 4139526
14 Wang L Zhu L Zhu H 2016 Efficacy of varicella (VZV) vaccination: an update for the clinician Ther Adv Vaccines 4 20 31 10.1177/2051013616655980 27551429
15 Sanford M Keating GM 2010 Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults Drugs Aging 27 159 76 10.2165/10489140-000000000-00000 20104941
17 Dagnew AF Ilhan O Lee WS Woszczyk D Kwak JY Bowcock S 2019 Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis Lancet Infect Dis 19 988 1000 10.1016/S1473-3099(19)30163-X 31399377
18 Warrington R Ismail S National Advisory Committee on Immunization (NACI) 2018 Summary of the NACI update on herpes zoster vaccines Can Commun Dis Rep 44 220 5 10.14745/ccdr.v44i09a06 31015813
19 Mullane KM Morrison VA Camacho LH Arvin A McNeil SA Durrand J 2019 Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial Lancet Infect Dis 19 1001 12 10.1016/S1473-3099(19)30310-X 31399378
20 Eberhardson M Hall S Papp KA Sterling TM Stek JE Pang L 2017 Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial Clin Infect Dis 65 1174 82 10.1093/cid/cix484 29126292
21 Parrino J McNeil SA Lawrence SJ Kimby E Pagnoni MF Stek JE 2017 Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies Vaccine 35 1764 9 10.1016/j.vaccine.2016.10.055 28268074
23 Lecrenier N Beukelaers P Colindres R Curran D De Kesel C De Saegher JP 2018 Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention Expert Rev Vaccines 17 619 34 10.1080/14760584.2018.1495565 30028651
25 Schmader KE Levin MJ Gnann JW Jr McNeil SA Vesikari T Betts RF 2012 Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years Clin Infect Dis 54 922 8 10.1093/cid/cir970 22291101
26 Oxman MN Levin MJ Johnson GR Schmader KE Straus SE Gelb LD 2005 A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2271 84 10.1056/NEJMoa051016 15930418
27 Schmader KE Oxman MN Levin MJ Johnson G Zhang JH Betts R 2012 Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy Clin Infect Dis 55 1320 8 10.1093/cid/cis638 22828595
28 Morrison VA Johnson GR Schmader KE Levin MJ Zhang JH Looney DJ 2015 Long-term persistence of zoster vaccine efficacy Clin Infect Dis 60 900 9 10.1093/cid/ciu918 25416754
29 Tseng HF Harpaz R Luo Y Hales CM Sy LS Tartof SY 2016 Declining effectiveness of herpes zoster vaccine in adults aged ≥60 years J Infect Dis 213 1872 5 10.1093/infdis/jiw047 26908728
30 Baxter R Bartlett J Fireman B Marks M Hansen J Lewis E 2018 Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study Am J Epidemiol 187 161 9 10.1093/aje/kwx245 29309521
31 Zussman J Young L 2008 Zoster vaccine live for the prevention of shingles in the elderly patient Clin Interv Aging 3 241 50 10.2147/CIA.S1225 18686747
32 Didierlaurent AM Laupeze B Di Pasquale A Hergli N Collignon C Garcon N 2017 Adjuvant system AS01: helping to overcome the challenges of modern vaccines Expert Rev Vaccines 16 55 63 10.1080/14760584.2016.1213632 27448771
33 Berarducci B Ikoma M Stamatis S Sommer M Grose C Arvin AM 2006 Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection J Virol 80 9481 96 10.1128/JVI.00533-06 16973553
34 Symoniak MR Farrokh P Gandhi MA Slish JC 2018 Herpes zoster subunit vaccine for the prevention of herpes zoster Am J Health Syst Pharm 75 861 9 10.2146/ajhp170399 29880523
35 Lal H Cunningham AL Godeaux O Chlibek R Diez-Domingo J Hwang SJ 2015 Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults N Engl J Med 372 2087 96 10.1056/NEJMoa1501184 25916341
36 Schwarz TF Volpe S Catteau G Chlibek R David MP Richardus JH 2018 Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults Hum Vaccin Immunother 14 1370 7 10.1080/21645515.2018.1442162 29461919
37 Lopez-Fauqued M Campora L Delannois F El Idrissi M Oostvogels L De Looze FJ 2019 Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials Vaccine 37 2482 93 10.1016/j.vaccine.2019.03.043 30935742
38 McGirr A Widenmaier R Curran D Espie E Mrkvan T Oostvogels L 2019 The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis Vaccine 37 2896 909 10.1016/j.vaccine.2019.04.014 30982636
39 Grupping K Campora L Douha M Heineman TC Klein NP Lal H 2017 Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine J Infect Dis 216 1343 51 10.1093/infdis/jix482 29029122
40 Dooling KL Guo A Patel M Lee GM Moore K Belongia EA 2018 Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines MMWR Morb Mortal Wkly Rep 67 103 8 10.15585/mmwr.mm6703a5 29370152
41 German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI) 2017 Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany: statement of the Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 60 1162 79 10.1007/s00103-017-2618-6 28879392
42 Siedler A Koch J Garbe E Hengel H von Kries R Ledig T 2019 Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62 352 76 10.1007/s00103-019-02882-5 30848293
43 Gabutti G Bolognesi N Sandri F Florescu C Stefanati A 2019 Varicella zoster virus vaccines: an update Immunotargets Ther 8 15 28 10.2147/ITT.S176383 31497569
※ AI-Helper는 부적절한 답변을 할 수 있습니다.